Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5795166 | 0.79 | MMP2 (0.50) | PTGS2ALDH1A1CA1CA2MMP1 | |
| SCHEMBL444872 | 0.79 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL488382 | 0.77 | GAA (0.59) | PTGS2ALDH1A1CA1CA2MMP1 | |
| Water SCHEMBL27918427 | 0.77 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL23145865 | 0.75 | ENPP2 (0.41) | PTGS2CA1CA2DRD1 | |
| SCHEMBL9628601 | 0.75 | CA2 (0.52) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL486726 | 0.75 | ALDH1A1 (0.56) | PTGS2ALDH1A1CA1CA2MMP1 | |
| SCHEMBL17642663 | 0.75 | CA1 (0.46) | PTGS2CA1CA2MMP1MMP2 | |
| SCHEMBL8577885 | 0.75 | SOS1 (0.52) | PTGS2ALDH1A1CA1CA2MMP1 | |
| SCHEMBL19833061 | 0.75 | EPAS1 (0.39) | PTGS2CA1DRD1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025073057-A1 | METHODS FOR PREPARING SULFILIMINES AND SULFOXIMINES FROM THIOETHERS USING O-(DIPHENYLPHOSPHINYL)HYDROXYL AMINE (DPPH), AND AMATOXIN ANALOGS PREPARED FROM SUCH METHODS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-04-10 | — | — | WO | disclosed |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| EP-3395818-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2021-09-22 | — | — | EP | disclosed |
| CN-110526847-B | Synthesis method of N-aryl sulfuryl sulfoxide imine | 成都理工大学 | 2021-01-19 | — | — | CN | disclosed |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-12-10 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-15 | — | — | US | disclosed |
| EP-3395818-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-31 | — | — | EP | disclosed |
| US-20180256591-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-9549932-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | PTGS2 158/4885ALDH1A1 1681/4885CA1 3022/4885 |
| US-20180256591-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | PTGS2 2043/4885ALDH1A1 1509/4885CA1 4885/4885 |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | PTGS2 2043/4885ALDH1A1 1509/4885CA1 4885/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | PTGS2 154/4885ALDH1A1 1490/4885CA1 3098/4885 |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MAP4K2, MAP3K20, MAP3K2 | PTGS2 1158/4885ALDH1A1 3510/4885CA1 4102/4885 |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | PTGS2 2043/4885ALDH1A1 1509/4885CA1 4885/4885 |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | PTGS2 2043/4885ALDH1A1 1509/4885CA1 4885/4885 |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | PTGS2 2043/4885ALDH1A1 1509/4885CA1 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.